CN Patent

CN121548409A — 沙芬酰胺的口腔分散药物固体剂型

Assigned to Intas Pharmaceuticals Ltd · Expires 2026-02-17 · 0y expired

What this patent protects

本发明涉及沙芬酰胺的口腔分散药物组合物，该药物组合物包含沙芬酰胺或其药学上可接受的盐、离子交换树脂以及一种或多种药物可接受的赋形剂，其中所述沙芬酰胺的口腔分散药物组合物用于治疗帕金森病。

USPTO Abstract

本发明涉及沙芬酰胺的口腔分散药物组合物，该药物组合物包含沙芬酰胺或其药学上可接受的盐、离子交换树脂以及一种或多种药物可接受的赋形剂，其中所述沙芬酰胺的口腔分散药物组合物用于治疗帕金森病。

Drugs covered by this patent

safinamide-mesylate (SAFINAMIDE MESYLATE)

Patent Metadata

Patent number: CN121548409A
Jurisdiction: CN
Classification: —
Expires: 2026-02-17
Drug substance claim: No
Drug product claim: No
Assignee: Intas Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.